Implicit Bioscience today announced its lead drug IC14 will be tested in a Phase 2 clinical trial in COVID-19 patients in 10 to 15 hospitals across the USA – which commenced this week. The trial, called the COVID-19 and Anti-CD14 Treatment Trial (“CaTT” NCT04391309), is sponsored and funded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health.
Courier Mail Medical Journalist, Janelle Miles, covered the story on page 4 – and it was widely syndicated via NewsCorp publications in metropolitan and regional areas too.